Navigation Links
Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
Date:9/24/2013

Irvine, CA (PRWEB) September 24, 2013

Proove Biosciences Inc., the leading personalized pain medicine laboratory, is proud to announce CEO Brian Meshkin has been selected as one of Howard County’s Finest Under 39. Meshkin is also the Vice Chairman of the Howard County Board of Education, and an avid supporter of causes to improve the lives of others.

The event honors young professionals who have demonstrated success in business, leadership in the community, and who are committed to fundraising for the Cystic Fibrosis Foundation. The event will be held on November 6, 2013 at 6pm, at the Turf Valley Resort and Conference Center.

The Maryland Chapter of the CFF is consistently a leader within the foundation through active volunteer participation and substantial fund-raising successes. Maryland Chapter volunteers plan, organize, and implement various fund raising projects throughout the year. The Finest Under 39 event will recognize honorees as prominent business leaders in the community, facilitate excellent networking opportunities, and promote fund raising towards helping to find a cure for Cystic Fibrosis.

“It is an incredible honor to be nominated by the CFF for this designation. The team at Proove Biosciences works hard to ensure we continue to produce industry leading research, as well as the tools that pain treatment professionals rely on daily,” stated Meshkin. “As the CEO of Proove, I understand the importance of genetic research, and will continue to support the efforts of the CFF in finding a cure for this disease.”

Cystic fibrosis is a devastating genetic disease that affects the lungs and digestive system. More than ten million Americans are symptomless carriers of the defective CF gene. Advances continue to be made in finding a cure, but help is needed now -- more than ever -- to help keep up the momentum of this life-saving research. When the Foundation began in 1955, most children with CF did not live to see their first day of elementary school. Today, the median predicted age of survival for a person with CF is in the mid-30s. This is remarkable progress, but not good enough. To learn more about CF and the CF Foundation, visit http://www.cff.org. To make a contribution to support this important research and support Brian’s fundraising effort, click here.

About Proove Biosciences
Proove Biosciences is a Personalized Pain Medicine company that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. Based in Southern California, physicians use Proove testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove Biosciences performs proprietary genetic tests in a CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2013/9/prweb11156213.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
2. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
3. James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
4. Microvi Biotechnologies Appoints Former COO of Zenon Environmental as Chairman of Board of Directors
5. Exosome Diagnostics Names Kapil Dhingra Chairman of the Board of Directors
6. BioRestorative Therapies Announces Chairman of Its Scientific Advisory Board to Speak at Vatican
7. Life Technologies Chairman And CEO Gregory T. Lucier Named Penn State Outstanding Engineering Alumnus
8. GlycoVaxyn AG announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors
9. Ernest Mario, Ph.D., Named Chairman of Chimerix, Inc.
10. VIASPACE Chairman and CEO Attend EUEC 2013, Giant King Grass Prominently Featured in Convention Exhibit Hall
11. California Healthcare Institute Appoints Allergan CEO Chairman of the Board, Elects New Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... /PRNewswire/ -  Equicare Health Inc ., the leading supplier ... one of the top 100 companies in the 2016 ... distinguishes the top digital health companies across the globe. ... this year continually upgrading our product with the ongoing ... team," says Len Grenier , CEO of Equicare ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader ... the implications of the latest FDA guidance on pharmaceutical cocrystals as drug substance ... Cambridge, MA. , The event follows the successful November 15th event that ...
(Date:11/30/2016)... ... November 30, 2016 , ... On 28 November 2016, ... for four elements: nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively ... review, the names earlier proposed by the discoverers have been approved by the IUPAC ...
Breaking Biology Technology:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):